

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A method for treating cognitive impairment, the method comprising a step of:

providing to a patient in need thereof an amount of one or more selective dopamine D1-like receptor agonists effective for treating the cognitive impairment using a dosing regimen that minimizes side effects and/or desensitization or tolerance to the treatment and/or provides for long term improvement in cognitive function and/or prevention of further deterioration of cognitive function.
2. (original) The method of Claim 1, further comprising a step of:

improving other symptoms related to an underlying disease or cause of the cognitive impairment.
3. (original) The method of Claim 1, further comprising a step of:

combining the selective dopamine D1-like receptor agonist with a second drug having some efficacy for treating an underlying disease or cause of the cognitive impairment.
4. (original) The method of Claim 3, wherein the second drug is a selective dopamine D2 receptor agonist.
5. (original) The method of Claim 4, wherein the selective dopamine D2 receptor agonist is haloperidol.
6. (original) The method of Claim 3, wherein the combination of the selective dopamine D1-like receptor agonist and the second drug acts additively or synergistically.
7. (original) The method of Claim 1, wherein the selective dopamine D1-like receptor

agonist is DAS-431.

8. (original) A method for generating a profile for correlating dopaminergic state to cognitive impairment, the method comprising steps of:
- determining a dopaminergic status and/or cognitive function of both individual patients with cognitive impairment and of a population of patients with cognitive impairment associated with a particular disease state or normal aging process; and
 - correlating the dopaminergic status and/or the cognitive function both in the individual patient and in the particular population of patients.

Claims 9-12 (cancelled)

13. (original) A pharmaceutical pack or kit for the treatment of cognitive impairment comprising one or more selective dopamine D1-like receptor agonist
14. (original) A pharmaceutical pack or kit for the treatment of cognitive impairment comprising one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist.
15. (original) The pharmaceutical pack or kit according to Claim 13 or Claim 14, wherein said dopamine D1-like receptor agonist comprises DAS-431.
16. (original) The pharmaceutical pack or kit according to Claim 14 or Claim 15, wherein said selective dopamine D2 receptor agonist comprises haloperidol.
17. (currently amended) A composition comprising one or more selective dopamine D1-like receptor agonist and a pharmaceutically acceptable carrier or excipient ~~for use as medicament for the treatment of cognitive impairment.~~
18. (currently amended) A composition comprising one or more selective dopamine D1-like receptor agonist and a selective dopamine D2 receptor agonist in a pharmaceutically

acceptable carrier or excipient ~~for use as medicament for the treatment of cognitive impairment.~~

19. (original) The composition according to Claim 17 or Claim 18, wherein said selective dopamine D1-like receptor agonist comprises DAS-431.

20. (original) The composition according to Claim 18 or Claim 19, wherein said selective dopamine D2 receptor agonist comprises haloperidol.

Claims 21-28 (cancelled)